191 related articles for article (PubMed ID: 37195923)
1. NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects.
Nicolaides NC; Kline JB; Grasso L
PLoS One; 2023; 18(5):e0285161. PubMed ID: 37195923
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
3. NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors.
Grasso L; Jiang Q; Hassan R; Nicolaides NC; Kline JB
Eur J Immunol; 2023 Aug; 53(8):e2250309. PubMed ID: 37146241
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
[TBL] [Abstract][Full Text] [Related]
5. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
7. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
8. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
9. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
10. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.
Xiang X; Feng M; Felder M; Connor JP; Man YG; Patankar MS; Ho M
J Cancer; 2011; 2():280-91. PubMed ID: 21611109
[TBL] [Abstract][Full Text] [Related]
11. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
[No Abstract] [Full Text] [Related]
12. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
[TBL] [Abstract][Full Text] [Related]
15. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
Nicolaides NC; Schweizer C; Somers EB; Wang W; Fernando S; Ross EN; Grasso L; Hassan R; Kline JB
Cancer Biol Ther; 2018 Jul; 19(7):622-630. PubMed ID: 29652548
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
Buongervino S; Lane MV; Garrigan E; Zhelev DV; Dimitrov DS; Bosse KR
Mol Cancer Ther; 2021 Nov; 20(11):2228-2239. PubMed ID: 34465595
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
19. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]